Oveporexton clinical trials
Also written TAK-861.
How each study uses oveporexton is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the oveporexton studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 5 Aug 2026 · ORZEYFUL · NDA 220860 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2023 | 3 |
| 2024 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test oveporexton, phase 3 first.
- Dec 2026A Trial of TAK-861 for the Treatment of Narcolepsy With CataplexyPhase 3 · Takeda
Studies
Open first, then newest update. How each study uses oveporexton is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study of TAK-861 for the Treatment of Selected Central Hypersomnia ConditionsRecruitingPhase 2/3TakedaNCT05816382Written as TAK-861
- A Trial of TAK-861 for the Treatment of Narcolepsy With CataplexyActive, not recruitingPhase 3TakedaNCT07363720Written as TAK-861
- A Study of TAK-861 for the Treatment of Narcolepsy Type 1CompletedPhase 3TakedaNCT06470828Written as Oveporexton
- A Study of TAK-861 in People With Narcolepsy Type 1CompletedPhase 3TakedaNCT06505031Written as TAK-861
- A Study of TAK-861 in Participants With Narcolepsy Type 2CompletedPhase 2TakedaNCT05687916Written as TAK-861 2 mg
- A Study of TAK-861 in Participants With Narcolepsy Type 1CompletedPhase 2TakedaNCT05687903Written as TAK-861
Codes
What other systems call oveporexton · ClinicalTrials.gg INT015047
- UNII (FDA) 59MF6P2ATFOVEPOREXTONConfirmed FDA, Wikidata
- Wikidata Q133270312oveporextonConfirmed FDA, Wikidata
- NCI Thesaurus C211734OveporextonOne source FDA
- DrugBank DB21680One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 59MF6P2ATF | OVEPOREXTON | Confirmed FDA, Wikidata |
| Wikidata | Q133270312 | oveporexton | Confirmed FDA, Wikidata |
| NCI Thesaurus | C211734 | Oveporexton | One source FDA |
| DrugBank | DB21680 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.